PRNewsWire
15 Sept 2026, 10:37 UTC · 1h ago
Verdict
Headline leans bearish. We score CAPR −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
An FDA advisory committee voted 9-3 against the efficacy of Deramiocel for treating DMD-associated cardiomyopathy.
Priced inreported July 30, 2026
So whatThis negative non-binding vote significantly increases the probability of a final FDA rejection, which would likely collapse the current $4.19 valuation.
More negative than 98% of claims this week
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The FDA expressed concerns that Capricor made post-hoc changes to its statistical analysis plan for the primary endpoint (PUL 2.0) shortly before unblinding data.
Priced inFDA briefing documents released July 27, 2026
So whatData integrity concerns often lead the FDA to require entirely new Phase 3 trials, extending the time-to-market horizon by several years.
More negative than 91% of claims this week
Capricor Therapeutics is facing a securities fraud class action lawsuit alleging the company misrepresented the integrity of clinical data for its lead candidate Deramiocel.
Priced inlawsuit refers to July 2026 stock drops
More negative than 80% of claims this week
The deadline for investors to move for appointment as lead plaintiff in the class action is September 28, 2026.
Newannouncement dated Sep 15, 2026
More negative than 62% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a massive stock price drop and FDA concerns over clinical data integrity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
—
CAPR hasn't traded since this ran. Last close $8.81 (Sep 14); the reaction starts at the next open.
CAPR chart →
